STS Biopolymers Grants License to Jomed for Stent Coating

A license agreement has been announced that grants rights to a drug delivery coating for stents developed by STS Biopolymers (Henrietta, NY, USA) to Jomed GmbH (Freiburg, Germany).

The drug delivery technology of STS Biopolymers enables single or multiple drug combinations to be released over controllable time periods, ranging from days to weeks or months. Used in combination with a primer called Bond-Coat, the coating is permanently adhered to a stent while providing the flexibility needed for placement and expansion. In a one-month coronary study in pigs, the polymer matrix was found to be biocompatible, with no increased inflammation reaction. Jomed is using the coating on stents to prevent restenosis.

"We are very pleased that Jomed has chosen to work with Biopolymers to utilize the Medi-Coat drug release coating for stents. Jomed has selected a proprietary drug technology for incorporation into the Medi-Coat coating,” said Richard Whitbourne, chairman of STS Biopolymers. "We expect the Jomed stent product to move very quickly to market, but to be followed by other important products using the Medi-coat coating platform.





Related Links:
STS Biopolymers
Jomed